Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1a/b Study of BG-C137 (FGFR2b-targeting ADC) in Advanced Solid Tumors
jRCT2031250591Phase 1Completed
- Sponsor
- BeOne Medicines
- Start
- Feb 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of BG-C137 in Nonhematologic neoplasms and carcinoma (2 arms), sponsored by BeOne Medicines. Primary endpoints: Number of Participants with Adverse Events and Serious Adverse Events (Phase 1a), Maximum Tolerated Dose or Maximum Administered Dose of BG-C137 (Phase 1a) and 3 more. Started Feb 2026; status: completed.
02
Drugs
BG-C137
03
Conditions
Nonhematologic neoplasmscarcinoma
Beyond the preview
Go deeper on jRCT2031250591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250591.